Skip to content
Evigrade
CriticalMacrolide antibiotic×Selective serotonin reuptake inhibitors (SSRIs)

Updated · Methodology

Mechanism

Escitalopram prolongs the QT interval in a dose-dependent way, and post-marketing reports describe QT prolongation and ventricular arrhythmia, including torsade de pointes (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Prolonged cardiac repolarisation and QT prolongation, with a risk of arrhythmia and torsade de pointes, have also been observed during erythromycin treatment (erythromycin SmPC, AEMPS). Escitalopram has not been studied with other QT-prolonging drugs, and the Spanish escitalopram SmPC does not rule out an additive effect on the QT interval (AEMPS). CYP2C19 is the main enzyme that metabolises escitalopram, with a smaller contribution from CYP3A4 and CYP2D6 (AEMPS). Erythromycin is a moderate CYP3A4 inhibitor (erythromycin SmPC, AEMPS), but even the strong CYP3A4 inhibitor ritonavir did not markedly change escitalopram pharmacokinetics, because several enzymes metabolise escitalopram (escitalopram label, US Food and Drug Administration, FDA).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while a ventricular arrhythmia causes palpitations, dizziness and fainting. QT prolongation and ventricular arrhythmia, including torsade de pointes, occur with escitalopram at unknown frequency. Post-marketing cases were seen mainly in women and in people with low potassium, pre-existing QT prolongation or other heart disease (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rare effects of erythromycin include QT prolongation, ventricular tachyarrhythmia, palpitations and torsade de pointes. Cardiac arrest and ventricular fibrillation occur at unknown frequency, and deaths have been reported with QT prolongation from macrolides, including erythromycin (erythromycin SmPC, AEMPS). Older people may be more susceptible to the effect of erythromycin on the QT interval (erythromycin label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated. The Spanish escitalopram summary of product characteristics (SmPC) contraindicates escitalopram with QT-prolonging drugs and lists intravenous erythromycin among them (escitalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Oral erythromycin is not named on that list, but the contraindication covers all QT-prolonging drugs, and the documents for oral erythromycin themselves state that it prolongs the QT interval (escitalopram and erythromycin SmPCs, AEMPS, and erythromycin label, US Food and Drug Administration, FDA). The erythromycin documents do not name escitalopram. They advise caution when erythromycin is given to people taking other QT-prolonging drugs (erythromycin SmPC, AEMPS). Escitalopram is contraindicated in people with a history of QT prolongation or congenital long QT syndrome. Erythromycin must not be given to people with a history of QT prolongation or ventricular arrhythmia, including torsade de pointes, or with low potassium or magnesium (escitalopram and erythromycin SmPCs, AEMPS). If escitalopram is withdrawn for an erythromycin course, taper the dose over at least 1–2 weeks rather than stopping it abruptly. When choosing another antibiotic, note that moxifloxacin is also contraindicated with escitalopram (escitalopram SmPC, AEMPS). The documents give no interval between stopping one drug and starting the other. The half-life is about 2 hours for erythromycin and about 30 hours for escitalopram (erythromycin and escitalopram SmPCs, AEMPS). If the drugs have nevertheless been taken together and signs of arrhythmia appear, stop escitalopram and record an electrocardiogram (escitalopram SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Erythromycin

Other interactions with Escitalopram